Ocumension Therapeutics
01477
Company Profile
Business description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Contact
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
SuzhouJiangsu
CHNT: +86 2161493800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
505
Stocks News & Analysis
stocks
ChatGPT enters the retail space and one company surges
Investors cheer the ability to purchase directly from ChatGPT.
stocks
Alibaba fair value increases by 49%
Stronger-than-expected AI demand internationally and domestically.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,146.50 | 8.90 | -0.10% |
| CAC 40 | 7,880.87 | 10.19 | 0.13% |
| DAX 40 | 23,745.06 | 5.59 | 0.02% |
| Dow JONES (US) | 46,316.07 | 68.78 | 0.15% |
| FTSE 100 | 9,299.84 | 15.01 | 0.16% |
| HKSE | 26,629.16 | 6.28 | 0.02% |
| NASDAQ | 22,591.15 | 107.09 | 0.48% |
| Nikkei 225 | 45,023.48 | 20.27 | -0.05% |
| NZX 50 Index | 13,162.09 | 29.53 | 0.22% |
| S&P 500 | 6,661.21 | 17.51 | 0.26% |
| S&P/ASX 200 | 8,860.80 | 8.50 | -0.10% |
| SSE Composite Index | 3,871.41 | 8.88 | 0.23% |